natgillin/translations-raw huggingface dataset:
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Imnovid’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Imnovidi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Incruse’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Incruse kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Invokana’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Invokana kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ionsys’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Ionsysi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Izba’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Izba kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Jardiance’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Jardiance kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Jinarc’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Jinarci kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kadcyla’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Kadcyla kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kanuma’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Kanuma kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kengrexal’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Kengrexali kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ketoconazole HRA’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Ketoconazole HRA kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Keytruda’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Keytruda kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kolbam’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Kolbami kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kovaltry’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Kovaltry kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Kyprolis’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Kyprolise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Latuda’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Latuda kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Laventair’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Laventairi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lenvima’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Lenvima kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lixiana’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Lixiana kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lojuxta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Lojuxta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lonsurf’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Lonsurfi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Lynparza’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Lynparza kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Mekinist’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Mekinisti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Mirvaso’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Mirvaso kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Moventig’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Moventigi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Neuraceq’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Neuraceqi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nexium Control’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Nexium Controli kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nivolumab BMS’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et ravimi Nivolumab BMS kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that NovoEight’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et NovoEighti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that NovoRapid’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et NovoRapidi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nucala’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Nucala kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nuedexta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Nuedexta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Nuwiq’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Nuwiqi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Odomzo’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Odomzo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ofev’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Ofevi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Olysio’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Olysio kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ongentys’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Ongentyse kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Onivyde’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Onivyde kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Opdivo’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Opdivo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Orbactiv’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Orbactivi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Orkambi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Orkambi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Otezla’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Otezla kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Praluent’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Praluenti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Procysbi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Procysbi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Provenge’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Provenge kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Qtern’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Qterni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Quinsair’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Quinsairi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Raplixa’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Raplixa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Relvar Ellipta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Relvar Ellipta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Repatha’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Repatha kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Revatio’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Revatio kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Revinty Ellipta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Revinty Ellipta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Rezolsta’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Rezolsta kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Ristempa’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Ristempa kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Rixubis’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Rixubise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Saxenda’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Saxenda kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Scenesse’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Inimravimite komitee otsustas, et Scenesse kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Senshio’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Senshio kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sevelamer carbonate Zentiva’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Sevelamer carbonate Zentiva kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sirturo’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Sirturo kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sivextro’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Sivextro kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Somatropin Biopartners’ benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Somatropin Biopartnersi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sovaldi’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Sovaldi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Stayveer’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Stayveeri kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Stelara’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Stelara kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Stivarga’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Stivarga kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Strensiq’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Strensiqi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Stribild’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Stribildi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Strimvelis’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Strimvelise kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Sylvant’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Sylvanti kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Synjardy’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Synjardy kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Tafinlar’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Tafinlari kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that Tagrisso’s benefits are greater than its risks and recommended that it be approved for use in the EU.
Inimravimite komitee otsustas, et Tagrisso kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.